KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $1.4 million.

  • Halozyme Therapeutics' Capital Expenditures fell 5324.38% to $1.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.0 million, marking a year-over-year decrease of 3483.55%. This contributed to the annual value of $7.0 million for FY2025, which is 3483.55% down from last year.
  • As of Q4 2025, Halozyme Therapeutics' Capital Expenditures stood at $1.4 million, which was down 5324.38% from $3.0 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Capital Expenditures ranged from a high of $11.4 million in Q1 2023 and a low of -$1.6 million during Q2 2023
  • Its 5-year average for Capital Expenditures is $2.0 million, with a median of $1.5 million in 2024.
  • Per our database at Business Quant, Halozyme Therapeutics' Capital Expenditures skyrocketed by 228164.56% in 2022 and then plummeted by 26766.53% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Capital Expenditures (Quarter) stood at $158000.0 in 2021, then skyrocketed by 2281.65% to $3.8 million in 2022, then tumbled by 31.01% to $2.6 million in 2023, then rose by 17.57% to $3.1 million in 2024, then crashed by 53.24% to $1.4 million in 2025.
  • Its Capital Expenditures stands at $1.4 million for Q4 2025, versus $3.0 million for Q3 2025 and $1.6 million for Q2 2025.